Meet us at the <br>ISCT 2021 New Orleans Virtual

Meet us at the 
ISCT 2021 New Orleans Virtual

May 26–28, 2021 

Expanding the possibilities in cell therapy manufacturing

At Miltenyi Biotec, we are committed to supporting clinical innovators and manufacturers with solutions and services that enable scalable clinical translation of novel cell and gene therapies. Join our symposium at the ISCT 2021 New Orleans Virtual and hear from your peers how they are expanding the possibilities to advance cell therapy. In our roundtable discussion we will delve into the question of whether there are platforms that significantly shorten clinical readiness for CAR T therapies.  

Moreover, you will find a selection of useful resources to enhance your development of advanced therapies and streamlined manufacturing processes. Continue reading to find out more about how we can help you expand the possibilities in cell therapy manufacturing. 

Artboard Copy Scientific program

Corporate Symposium

Expanding possibilities for advancing cell therapy

In this symposium you have the chance to meet Boris Fehse who established a mRNA electroporation protocol for the automated production of CCR5-edited CD4+ T cells on the CliniMACS Prodigy® to prevent HIV infection. Sandy Pelletier will outline her approach to isolate tumor-reactive T cells from solid tumors using the MACSQuant® Tyto® Cell Sorter. Last but not least, Moonsoo M. Jin presents his work with affinity-tuned CAR T cells to target solid tumors with high-level antigen expression.

Thursday, May 27, 2021
8:30 a.m. – 10:00 a.m. PDT | 11:30 a.m.–1:00 p.m. EDT | 5:30 p.m.–7:00 p.m. CEST

Clinical scale CCR5 knockout in primary T cells in the CliniMACS Prodigy

Speaker: Boris Fehse
University Medical Center Hamburg-Eppendorf, Germany 

Knocking out the HIV co-receptor CCR5 by gene editing is promising clinical strategy to protect CD4+ T helper cells from HIV infection. We have developed a GMP-compatible mRNA electroporation protocol for delivery of our high-efficiency CCR5-specific TALEN using the CliniMACS Prodigy System. The automated process reliably produced clinical-scale amounts of CCR5-edited CD4+ T cells (>1.5x109 cells with >60% CCR5 editing) within 12 days.

About Boris Fehse
Prof. Dr. Boris Fehse is Professor for Cell and Gene Therapy and Head of the Research Department Cell and Gene Therapy within the Department of Stem Cell Transplantation of the University Medical Center Hamburg-Eppendorf (UKE), Germany. Prior to joining UKE, he held an appointment as Professor for Experimental Pediatric Oncology and Hematology at the University Hospital of the Johann Wolfgang Goethe University Frankfurt, Germany. Prof. Fehse graduated in Biomedicine at the Russian State Medical University of Moscow, Russia (German M.D. in Theroretical Medicine) and obtained his Ph.D. in Molecular Biology at the Heinrich-Pette-Institute and the University of Hamburg. He did his postdoctoral training at the Bone Marrow Transplantation Center of the UMC Hamburg and spent a research period abroad at the NIH in Bethesda, USA, after having received a grant of the German American Academic Council (GAAC).  

Read more …
Harnessing the power of tumor-infiltrating lymphocytes

Speaker: Sandy Pelletier
CHUM Research Center, Montreal, Canada

Although cell therapy for the treatment of cancer has shown success, many challenges persist. Our approach includes successfully isolating tumor-reactive T cells from solid tumors using the MACSQuant Tyto – a GMP-compliant flow cytometry-based cell sorter – with the purpose of using these cells for tumor-infiltrating lymphocyte adoptive cell transfer

About Sandy Pelletier
Sandy Pelletier, Ph.D., is Scientific Coordinator of the Adoptive Cell Transfer (ACT) Immunotherapy Program at CHUM Research Center, Montreal, Canada, where she also worked as Research Associate from 2013 to 2016. Her current responsibilities include coordinating the development of a phase I/II clinical trial, setting up new clean room for GMP manufacturing, and generating and analyzing pre-clinical data. Sandy Pelletier obtained her Ph.D. from the Université de Montréal, Canada.  

Read more …
Affinity-tuned CAR T to treat tumors with overexpressed antigens: Phase I study against advanced thyroid cancer

Speaker: Moonsoo M. Jin
Molecular Imaging Innovations Institute (MI3), New York, USA          

We developed affinity-tuned ICAM-1 targeting CAR T cells to be selective to tumors with overexpressed ICAM-1. Our CAR has SSTR2 that allows PET/CT monitoring of CAR T distribution in patients. I’ll also talk about CAR T manufacturing, general strategy of affinity-tuning, and ways to elevate CAR T activity.

About Moonsoo M. Jin                 
Moonsoo M. Jin, Ph.D., is a biomedical engineer with expertise and training in molecular and cellular engineering, nanoparticles for imaging and drug delivery, and whole-body imaging techniques. Using multiscale biomedical tools, his research is focused on developing technology concerned with therapy and diagnosis of cancer and inflammation-associated diseases. He currently serves as director of the Molecular Imaging Innovations Institute (MI3), New York, USA.

Read more …


Are there platforms that significantly shorten clinical readiness for CAR T therapies?

Join Kunal Patel, Process Engineering Manager at Miltenyi Biotec, amongst others panelists and delve into the question of whether there are platforms that significantly shorten clinical readiness for CAR T therapies.

Friday, May 28, 2021
12:00 p.m.–1:00 p.m. PDT | 3:00  p.m.–4:00 p.m. EDT |  9:00 p.m.–10:00 p.m. CEST

Not registered yet?

Only participants of the ISCT Virtual Meeting can access the scientific program
through the event platform. 



icon Resources download

On-demand education

Contact us

If you would like a Miltenyi Biotec representative to contact you after the congress 
please complete the form below.

I would like to speak to a representative about the following Miltenyi Biotec technologies and solutions:

Contact information

* Mandatory field
Miltenyi Biotec B.V. & Co. KG collects and process data submitted herein in accordance with Miltenyi’s Privacy Statement.